Kezar Life Sciences Revenue and Competitors

Location

$123M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kezar Life Sciences's estimated annual revenue is currently $10.5M per year.(i)
  • Kezar Life Sciences's estimated revenue per employee is $119,773
  • Kezar Life Sciences's total funding is $123M.
  • Kezar Life Sciences's current valuation is $755.4M. (January 2022)

Employee Data

  • Kezar Life Sciences has 88 Employees.(i)
  • Kezar Life Sciences grew their employee count by 60% last year.

Kezar Life Sciences's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$750M4907-3%$149.1MN/A
Add Company

What Is Kezar Life Sciences?

We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.

keywords:N/A

$123M

Total Funding

88

Number of Employees

$10.5M

Revenue (est)

60%

Employee Growth %

$755.4M

Valuation

N/A

Accelerator

Kezar Life Sciences News

2022-04-20 - Kezar Life Sciences (NASDAQ:KZR) Rating Reiterated by ...

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics...

2022-04-13 - Kezar Announces Inducement Grant Under NASDAQ Listing ...

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and...

2022-03-22 - Best Places to Work in the Bay Area Awards - San Francisco ...

Herrero Builders Inc. Hirsch Philanthropy Partners Hotel Nikko San Francisco Intercom Johanson & Yau Joseph J. Albanese, Inc. Kezar Life Sciences Lively

2017-07-25 - Kezar Life Sciences Secures $50M in Series B Financing

Kezar Life Sciences, a South San Francisco, Calif.-based clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting the immunoproteasome and the protein secretion pathway, closed a $50m Series B funding. The round was led by Cormorant Asset Management and Mo ...

2017-07-25 - Cormorant Leads $50M Series B for Kezar Life Sciences

Kezar Life Sciences, a private, clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting the immunoproteasome and the protein secretion pathway, announced today that it has closed an oversubscribed Series B investment round of $50 million led by Cormorant A ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.6M88-4%N/A
#2
$12.8M88-8%N/A
#3
$12.8M88N/AN/A
#4
$12.8M88N/AN/A
#5
$17.8M88-11%$20M